Abstract:Cystic fibrosis (CF) is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas. People with CF often have malnutrition and growth delay. Adequate nutritional supplementation does not improve growth optimally and hence an anabolic agent, recombinant human growth hormone (rhGH), has been proposed as a potential intervention. This is an update of a previously published review. To evaluate the effectiveness and safety of rhGH therapy in improving lung function, quality of life and clinical status of children and young adults with CF. We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of latest search: 12 January 2021. We also searched ongoing trials registers: clinicaltrials.gov from the United States ‐ date of latest search 19 Jun 2021; WHO International Clinical Trials Registry Platform (ICTRP) ‐ date of latest search 05 March 2018 (not available in 2021). We conducted a search of relevant endocrine journals and proceedings of the Endocrinology Society meetings using Web of Science, Scopus and Proceedings First. Date of latest search: 21 Jun 2021. Randomised and quasi‐randomised controlled trials of all preparations of rhGH compared to either no treatment, or placebo, or each other at any dose (high‐dose and low‐dose) or route and for any duration, in children or young adults (aged up to 25 years) diagnosed with CF (by sweat test or genetic testing). Two authors independently screened papers, extracted trial details and assessed their risk of bias. We assessed the quality of the evidence using the GRADE system. We included eight trials (291 participants, aged between five and 23 years) in the current version of the review. Seven trials compared standard‐dose rhGH (approximately 0.3 mg/kg/week) to no treatment and one three‐arm trial (63 participants) compared placebo, standard‐dose rhGH (0.3 mg/kg/week) and high‐dose rhGH (0.5 mg/kg/week). Six trials lasted for one year and two trials for six months. We found that rhGH treatment may improve some of the pulmonary function outcomes, but there was no difference between standard and high‐dose levels (low‐certainty evidence, limited by inconsistency across the trials, small number of participants and short duration of therapy). The trials show evidence of improvement in the anthropometric parameters (height, weight and lean body mass) with rhGH therapy, again no differences between dose levels. We found improvement in height for all comparisons (very low‐ to low‐certainty evidence), but improvements in weight and lean body mass were only reported for standard‐dose rhGH versus no treatment (very low‐certainty evidence). There is some evidence indicating a change in the level of fasting blood glucose with rhGH therapy, however, it did not cross the clinical threshold for diagnosis of diabetes in the trials of short duration (low‐certainty evidence). There is low‐ to very low‐certainty evidence for improvement of pulmonary exacerbations with no further significant adverse effects, but this is limited by the short duration of trials and the small number of participants. One small trial provided inconsistent evidence on improvement in quality of life (very low‐certainty evidence). There is limited evidence from three trials in improvements in exercise capacity (low‐certainty evidence). None of the trials have systematically compared the expense of therapy on overall healthcare costs. When compared with no treatment, rhGH therapy is effective in improving the intermediate outcomes in height, weight and lean body mass. Some measures of pulmonary function showed moderate improvement, but no consistent benefit was seen across all trials. The significant change in blood glucose levels, although not causing diabetes, emphasizes the need for careful monitoring of this adverse effect with therapy in a population predisposed to CF‐related diabetes. No significant changes in quality of life, clinical status or side‐effects were observed in this review due to the small number of participants. Long‐term, well‐designed randomised controlled trials of rhGH in individuals with CF are required prior to routine clinical use of rhGH in CF. Review question We reviewed the evidence about the effects of recombinant human growth hormone (rhGH) on the health of people with cystic fibrosis (CF). Background CF is an inherited condition causing disease in the lungs, digestive system and pancreas. People with CF are often underweight and have delayed growth, which may impact their lung function. Nutritional supplements may not be enough and it has been suggested that treatment with rhGH, which improves the rate of growth and bone density, might help. Treatment with rhGH -Abstract Truncated-

Nutritional Rehabilitation in Cystic Fibrosis

Evaluation of Growth and Changes in Body Composition Following Neonatal Diagnosis of Cystic Fibrosis

A randomized controlled trial of a new behavioral home-based nutrition education program, "Eat Well with CF," in adults with cystic fibrosis

Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial

Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators

Gastrointestinal Dysfunction and Its Effects on Nutrition in CF

Trends in Growth and Maturation in Children with Cystic Fibrosis Throughout Nine Decades

Improving growth in infants with CF

Nutritional status and pulmonary outcome in children and young people with cystic fibrosis

Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis

The Risk of Developing of Malnutrition and the Principles of Correction of Nutritional Status Disorders in Children with Cystic Fibrosis

Improving gastrointestinal health in children and young people with cystic fibrosis

Impact of CF summer camp

Evolution of nutritional management in children with cystic fibrosis – a narrative review

[Gastrointestinal manifestations of cystic fibrosis in children]

Association Between Practice Patterns and Body Mass Index Percentile in Infants and Young Children with Cystic Fibrosis

Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndrome

Recombinant growth hormone therapy for cystic fibrosis in children and young adults.

Early Intestinal Rehabilitation Therapy Ameliorates Intestinal Adaptation in Children with Short Bowel Syndrome: The Long-Term Outcome

The association between gut microbiome and growth in infants with cystic fibrosis

Oral Nutritional Supplements in Adults with Cystic Fibrosis: Effects on Intake, Levels of Fat-Soluble Vitamins, and Bone Remodeling Biomarkers